Latest News

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

Pooled FIBRONEER trial data show nerandomilast reduced the risk of death by up to 43% versus placebo, though the analysis was post hoc.

John Giacona, PhD, PA-C, discusses building a comprehensive multidisciplinary care team for interstitial lung disease and how APPs should engage with clinical evidence.

The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.

The ACC's new decision pathway incorporates SGLT2 inhibitor finerenone and data on incretin therapy into HFpEF diagnosis and management guidance.

MV130, a sublingual mucosal trained immunity vaccine, showed significant benefits vs placebo, with benefit sustained after treatment ended.

Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.

John Giacona, PhD, PA-C, discusses the cardiology perspective on screening for and managing pulmonary hypertension in interstitial lung disease.

CaRi-Heart measures coronary inflammation from routine CT angiography and generates a personalized 10-year cardiovascular mortality risk score.

Pfizer reported positive topline phase 3 results, with significant improvements in facial and total repigmentation at week 52 versus placebo.

Moderator Greg Bensch and a panel of allergists discuss itch control, access barriers, and guideline gaps shaping newer AD topicals in this clinical forum.

Phoenix PAH specialists discuss RHC-guided monitoring, sotatercept shunting and erythrocytosis signals, meth-PAH management, and prostacyclin transition strategies.

How should clinicians choose atopic dermatitis treatments? Harrison Nguyen, MD, discusses personalized therapy and when to escalate care.

Andrew Adams discusses tegoprubart in kidney transplantation and the phase 2 BESTOW data on kidney function, rejection, and immunosuppression.

PAH specialists discuss prostacyclin use, pericardial effusion risks, erythrocytosis, and what real-world super-responders look like in practice.

Topline data from the largest disease-modification trial in biliary atresia show no benefit over placebo for the primary endpoint, though the established safety profile in approved indications was maintained.

In this episode of The Medical Sisterhood, physician entrepreneurship is explored as Meagen McCusker, MD, shares lessons on private practice, leadership, and career.

In the OUTMATCH stage 2 randomized trial, omalizumab achieved greater intention-to-treat success than multiallergen oral immunotherapy.

World Hepatitis Day survey findings reveal gaps in chronic hepatitis B awareness and liver cancer risk perception, with Cary James discussing elimination efforts.

The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.

Organon reports pooled phase 3 data showing tapinarof cream (VTAMA) improved atopic dermatitis severity across pediatric and adult age groups by Week 8.

The Voluntary Sodium Reduction Goals, issued in October 2021, resulted in no significant reduction in sodium content among packaged foods.

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.